PROC
Procaps Group S.A.
Set alert
- YTD
- 0.00%
- 1 year
- 0.00%
- Open
- 1.01
- Prev close
- 1.01
- Mkt cap
- 297.86M
- Vol
- 652.30K
- Avg vol
- 98.16K
- EPS
- 0.51
- P/E
- 5.18
- Div yield
- 0.00%
More statistics
- Low
- 1.01
- High
- 1.01
- Forward P/E
- 9.78
- Beta
- 0.17
- Short ratio
- 1.08
- Inst. own
- 2.93%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Dec 24, 2024
- 50-d avg
- 1.76
- 200-d avg
- 2.30
- 1y target
- 0.00
Key statistics
- Market cap
- 297.86M
- Enterprise value
- 525.07M
- Trailing P/E
- 5.18
- Forward P/E
- 9.78
- PEG ratio
- 0.00
- Price / sales
- 0.72
- Price / book
- 6.77
- EPS (TTM)
- 0.51
- Beta
- 0.17
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 12.61%
- Revenue (TTM)
- 414.10M
- Revenue growth
- 7.30%
- Free cash flow
- -12.18M
- Total cash
- 17.56M
- Total debt
- 289.92M
- Return on equity
- 373.70%
- Shares outstanding
- 112.82M
- Short % of float
- 0.00%
- 50-day average
- 1.76
- 200-day average
- 2.30
Analyst view
Consensus: hold
- Strong buy0
- Buy0
- Hold1
- Sell0
- Strong sell0
Next earnings
Dec 24, 2024
Expected Dec 24, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Dec 24, 2024 | Sep 1, 2024 | 0.00 | — | — | — |
| Oct 1, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| Jul 1, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| May 10, 2024 | Dec 1, 2023 | 0.09 | — | — | — |
| Sep 5, 2023 | Jun 1, 2023 | 0.06 | 0.27 | +0.21 | +350.00% |
| Jun 5, 2023 | Mar 1, 2023 | -0.04 | 0.07 | +0.11 | +275.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 6, 2023 | Brookline Capital | down | Buy | Hold |
About Procaps Group S.A.
Procaps Group S.A. develops, produces, and markets pharmaceutical solutions worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory. It also provides drugs for hospital use, such as antibiotic, blood clot, personal protective equipment, immunosuppressant, oncology, and analgesics products. In addition, the company offers over-the-counter (OTC) consumer healthcare products through a portfolio on approximately eight therapeutic areas, including gastrointestinal, skin care, cough and cold, analgesics, urological, vitamins, minerals, and supplements in the categories of antibiotics, anti-infective, anti-parasitic, cardiovascular, feminine care, cutaneous antimycotic, pain killers, gastro intestinal, hormonals, metabolic, endocrine, nervous system, ophthalmic, osteoarticular, respiratory, diet supplements, and vitamins and minerals. Further, it provides blood glucose meters, telemonitoring products, oral anti-diabetics products, cosmeceuticals, insulin delivery systems, and other diabetes solutions; and contract drug development and manufacturing services to third party pharmaceutical companies, specializing in soft gelatin capsule technologies. The company was founded in 1977 and is based in Luxembourg, Luxembourg.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- Luxembourg
- Website
- procapsgroup.com
News
- Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 2026
- /C O R R E C T I O N - AbbVie/
- Lilly to showcase advances across its oncology pipeline at the 2026 European Society for Medical Oncology (ESMO) Congress
- AbbVie to Present Data at the 2026 European Society for Medical Oncology (ESMO) Congress Highlighting Progress Across its Expanding Solid Tumor Portfolio
- Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer
- ProCook Group (LON:PROC) Trading Up 5.9% – Should You Buy?
- Zentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROC
- Procaps Group Secures $130 Million in Equity Investment and Completes Comprehensive Debt Restructuring, as New Investors Take Over Strategic Leadership
- Corcept Therapeutics: New PROC SOC Treatment Option With Relacorilant Data Release
- 12 Health Care Stocks Moving In Monday's Pre-Market Session
Your note
Sign in to keep a note on PROC — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Exome Asset Management LLC | 0.11% | 126,901 | 335.02K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.03% | 28,938 | 76.40K | Sep 29, 2024 |
| Activest Wealth Management | 0.01% | 10,000 | 26.40K | Sep 29, 2024 |
| Pineridge Advisors LLC | 0.00% | 250 | 660 | Sep 29, 2024 |
| Morgan Stanley | 0.00% | 100 | 264 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.03% | 28,938 | 76.40K | Oct 30, 2024 |
| SPDR Portfolio Emerging Markets ETF | 0.00% | 150 | 396 | Sep 29, 2024 |